Our portfolio

Descriptor

Innovative technology to identify small molecule drug candidates for CNS disorders. Pipeline includes 4 programs with the lead product in several phase II clinical trials.

A unique partnership model for the creation and acceleration of cardiovascular devices into the market.

Developing 'best in class' small molecule drugs for Type II diabetes and Osteoarthritis/inflammation based diseases. Apart from the lead product (DPPIV inhibitor in phase I clinical trials) Alantos has 5 programs in various stages of preclinical development.

Developing and commercialising novel therapeutics derived from the innate human immune system to treat a range of infectious and inflammatory diseases. The lead product is currently in phase II clinical trials for sepsis and IBD.

Gene based medicine targeting inherited metabolic disorders, ocular diseases and neurotherapy. The company’s lead product is currently advancing phase II trials in patients with lipoprotein lipase deficiency type I.

Combines an in-licencing and M&A driven strategy to commercialize research carried out by the Medical Research Council (MRC) Human Reproductive Sciences Unit (HRSU) in Edinburgh, Scotland. Besides 2 marketed products Ardana has a number of compounds in clinical development.

Co-ordinating medicinal chemistry, assay development and screening, ADMET and CADD to provide a complete solution to drug discovery research. Argenta combines fee-for-service work with a number of in-house therapeutics programmes focused on respiratory disease.

Treatment of metastatic cancers and chronic infections using a proprietary platform technology, involving stimulating immune cells with messenger RNA. The lead program for treatment of metastatic renal cell carcinoma is currently in phase I/II followed by four pre-clinical programs.

Focused on the use of herpes simplex virus as a biological treatment for cancer, Biovex is currently performing phase II trials for its lead product OncoVex.

Focused on the treatment of advanced heart failure patients, CircuLite's microvad system's pump is designed to solve the problems of mechanical failure and blood clotting exhibited in artificial hearts and pumps.

Product-oriented biopharmaceutical company focused on the research and development of new and critical agents for immune modulation. The lead compound recombinant human interleukin-7 is a critical growth factor for T cells with unique features to rebuild the immune system and global enhancement of immune system functions

Flowmedica has developed novel, proprietary, minimally invasive intravascular systems for implementing targeted renal therapy. Three infusion systems have been developed and provide an alternative to the standard delivery methods of systemic intravenous infusion to address kidney dysfunction related to a number of diseases.

Developing and commercializing drugs for the treatment of ocular diseases, with a special focus on retinal pathologies. Fovea has multiple clinical programs ongoing in retinal degeneration, macular edema, glaucoma, and inflammation.

Gene transfer technology for effective ex vivo human delivery of proprietary genes to treat serious genetic and chronic disorders such as thalassemia and sickle cell anemia

Designs and develops percutaneous transcatheter devices for the treatment of mitral valve regurgitation (a significant factor in congestive heart failure.)

PanGenetics is focused on the in-licensing and development of therapeutic antibodies. The lead program has been in a phase II study as chimeric antibody and its humanized counterpart will start clinical testing in 2007.

Develops innovative medical devices for the treatment of arterial diseases with an initial focus on peripheral artery disease (PAD).

Engaged in the discovery and development of Anticalins for the diagnosis and treatment of life-threatening human disorders. The two proprietary therapeutics programs, targeting CTLA-4 and VEGF respectively, are advancing in preclinical development.

Developing treatments for oncology, based on proprietary third generation RNA chemistry, Locked Nucleic Acid. Apart from its lead product in phase I/II, Santaris’ pipeline consists of 6 products in various stages of preclinical development.

Focused on the site specific treatment of lung diseases via the use of proprietary Sustained release Lipid Inhalation Targeting (SLITTM) technology. Transave’s lead product, SLIT-Amikacin, has received FDA and EMEA Orphan Drug designation and is in phase II trials in cystic fibrosis.

Integrated drug eluting stent (DES) company developing next-generation solutions for restenosis and other cardiovascular clinical applications. X-Cell’s lead program uses 17-ß-estradiol on DES which enhances endothelial growth to help combat sub-acute thrombosis.

Developing a pipeline of ion channel drugs across a number of indications. Xention is currently undertaking a number of projects in the neurological and cardiovascular areas.